The role of microsatellite instability to predict clinical benefit from irinotecan-based regimens in metastatic colorectal cancer

Artaç M., Pehlivan S., Akcan S., Pehlivan M., Gelen T., Itirli G., ...Daha Fazla

Turkish Journal of Cancer, cilt.38, sa.2, ss.49-56, 2008 (Scopus) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 38 Sayı: 2
  • Basım Tarihi: 2008
  • Dergi Adı: Turkish Journal of Cancer
  • Derginin Tarandığı İndeksler: Scopus, Academic Search Premier
  • Sayfa Sayıları: ss.49-56
  • Anahtar Kelimeler: Colon cancer, Irinotecan, Microsatellite instability, PCR
  • İstanbul Üniversitesi Adresli: Hayır

Özet

The aim of our study was to assess the relationship between microsatellite instability (MSI) and the clinical outcome in metastatic colorectal cancer (CRC) patients treated with irinotecan-based regimens. We assessed best objective response, progression free survival (PFS) and overall survival (OAS) in relation to MSI analysis that was performed using BAT-25, BAT-26, D5S346, D2S123, D17S250 markers in normal and tumor DNA. The best objective response was significantly and negatively related with the D17S250 (an adjacent locus to p53) microsatellite marker (p=0.047). However, MSI score was not related with the best objective response (p=0.88). There was again no relationship between PFS, OAS and MSI score. In conclusion, this study allowed us to establish in a prospective study design that MSI status did not predict survival in metastatic colorectal cancer patients treated with irinotecan-based regimens.